COMP <GO>
CTY vs HROW // EV/EBITDA & P/E VALUATION
City Therapeutics Inc. (NASDAQ) VS. Harrow Inc. (NASDAQ) • 15-METRIC TALLY: CTY 1
— HROW 1
■ METRIC PARITY
LAST: $22.14 (+2.26%) • MKT CAP: $1.11B
valuation
—
LAST: $29.99 (+2.04%) • MKT CAP: $1.12B
valuation
33.6x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (CTY VS. HROW)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | CTY | HROW | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 75.10% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 42.90% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | — | 33.6x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.82% | — | TIE | /fcf-yield <GO> |
| Operating Margin | — | 11.20% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -1.90% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 36.40% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 2.67 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | — | 7/9 | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 61.6 | 38.5 | +23.06 | CTY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.11B | $1.12B | -$9.9M | HROW | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | CTY REV | HROW REV | CTY GROSS % | HROW GROSS % | CTY FCF | HROW FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $272.3M | — | 75.1% | — | $43.0M |
| FY 2024 | — | $199.6M | — | 75.3% | — | -$23.8M |
| FY 2023 | — | $130.2M | — | — | — | $3.8M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
CTY // BETA —
HROW // BETA —